Rise of the machines, velvet divorces, GPT-4 in IR, BOREALIS - The titles of the scientific talks at this year's CIRSE are riveting! It is the biggest IR event of the year globally, and for us also at CASCINATION.
We highlight below what we think are the "can't miss" sessions for all attendees - including of course what we have going on from our company (CAS-One IR AI challenge, our Scientific Dinner and DJ party).
Posters online Sept 4
CIRSE is a large, comprehensive 4.5 day event. While topics covering Interventional Oncology are not typically the main focus, they are still very present. The CAS-One IR team will also be very present, and we highlight below, what we believe is most relevant for ablation aficionados.
In our heavily-biased opinion, the most exciting event at CIRSE 2024 is the launch of CAS-One IR 4.3 software. This new release brings many new things, but the major features are a lesion-based workflow, enhanced multi-needle capabilities, a reablation workflow, and an even more powerful AI-Driven AblaSure. You can see our landing page for more details
There are other NEW things about CAS-One IR coming we will share - but you really need to see them in person to understand...
.png?width=1200&length=1200&name=image%20(64).png)
You can also take part in this year’s CAS-One IR AI Challenge - version 4. Over 100 participants have competed since 2023 in various editions at 10 congresses.
The last winners were Professor Shu-Huei Shen from Veterans General Hospital (TW) for 1st place, and Dr. Donatas Jocius from Vilnius University Hospital (LT) for a second place finish, and Dr. Boglarka Toth from Semmelweis University Hospital (HU) for third place at ECIO 2025 in Rotterdam . Come by and compete for a prize.
.webp?width=1200&length=1200&name=WhatsApp%20Image%202025-04-16%20at%2016.57.07%20(2).webp)
.webp?width=1200&length=1200&name=WhatsApp%20Image%202025-04-16%20at%2016.57.07%20(1).webp)
SPHAIRE returns for the second year: what we think the highlights are have been included in our Scientific Agenda highlights below
On Monday Sept. 15th, we are hosting our own scientific dinner and after party. At the beautiful Terazza Miramar restaurant, we have 3 speakers highlighting Ablation Confirmation, as well as Kidney Ablation with CAS-One IR. Contact CASCINATION to reserve your spot today.
There will as usual be multiple posters featuring CAS-One IR - on September 4th they will be online in advance of the congress.
Scientific Highlights CIRSE 2025
Now, for the complete scientific highlights:
Saturday September 13th
FS 112 – Intrahepatic cholangiocarcinoma- what can you offer? 8:30-9:30 Room 115
112.2 / Percutaneous ablation - O. Moschovaki-Zeiger
IRT 126 – Future technologies in IR 10:00–11:00 Room 113
126.2 / Future IO technologies - A. Bibok
126.4 / Future MSK IR technologies - E. Di Gaeta
MPJ 132 – MSK Interventional Oncology 11:30–12:30 Room 112
132.2 / Percutaneous ablation for vertebral metastases -J. Levy
132.3 / Percutaneous ablation for osseous metastases in the peripheral skeleton - R. Cazzato
132.6 / Bringing it all together: the optimal modality combination algorithm for osseous metastases -J. Jennings
FC 133 – So you are an IR - but are you really a clinician? 11:30–12:30 Room 115
133.1 / Ward rounds and inpatient consultations - M. Lee
133.2 / MDT: how to participate in one and raise your profile as an IR - M. Calandri
133.3 / IR clinics need dedicated staff, time, and space - C. Binkert
133.4 / What are the advantages of an IR day unit? How do I set one up? -J. Cobos Alonso
MPI 141 – Meet the PI: cutting edge trials in IO - 13:00-14:00 News on stage
141.1 / BOREALIS: a prospective multicentre observational study on curative-intent cryoablation for bone metastases - R. Cazzato
ERT 162 – Colorectal cancer: liver metastatic disease - 16:15-17:15 Room 117
162.1 / Role of liver transplantation: which patient, when? - D. Ghinolfi
162.3 / How do research trials change the role of ablation? - H. Scheffer
162.4 / Non-thermal ablative treatments: level of evidence - G. Narayanan
SPH 169 – AI in IR: pre, post and intraprocedure prediction models - 16:15-17:15 News on stage
169.1 / Current status of pre, post and intraprocedure prediction models - T. Boeken
169.4 / 3D CBCT AI Denoising boosts image quality for procedures and enables gains in spatial resolution - N. Schnellbächer
SP 176 – Liver tumour board -17:30-18:30 Room 118
176.1 / Prognostic value of categorizing colorectal liver metastases (CRLM) into synchronous, early metachronous, and late metachronous based on detection time interval: survival outcomes from the Amsterdam Colorectal Liver Met Registry (AmCORE) - H. Schulz
176.2 / Nationwide strategies and outcomes of minimally invasive versus open combined liver resection and ablation for colorectal liver metastases - K. Balasupramaniam
176.3 / Circulating tumor DNA conversion status is associated with disease recurrence/progression following curative-intent microwave ablation of colorectal liver metastases - N. Siddiqi
Sunday September 14th
FS 222 – Ablative therapies for HCC and liver mets - 10:00–11:00 Auditorium 2
222.1 / Ablation for HCC according to the interventional radiologist - L. Crocetti
222.3 / The right patient for the right procedure in liver oligo mets: IR's point of view - M. Meijerink
SPH 228 – AI in IR: education, navigation and workflow optimisation - 10:00-11:00 News on stage
228.1 / Can GPT-4 match expert interventional radiologists? ACR guideline adherence in interventional radiology - A. Turgan
228.2 / Augmented reality in interventional radiology: a pilot study of user feedback and ergonomic impact - F. Cornelis
228.5 / MyNeedle companion with laser navigation system for renal cryoablation: technical considerations on a cohort of 20 patients - T. Cascella
228.7 / NeedleVue technology: AI-enhanced procedure planning, guidance, and needle visualization under ultrasound - A. Abo
FS 269c - Liver cancer and quality assurance: integrating clinical excellence with safe practice - 16:15–17:15 Room 113
269c.1 / Safety and efficacy of irreversible electroporation in hepatic hilar tumours - R. Gobbo
269c.2 / Value-driven healthcare in locoregional treatments of hepatocellular carcinoma 269c.3 / Optimizing liver tumour ablation: technical protocols and quality assurance - R. Cazzato
269c.4 / Integrating multidisciplinary care and data-driven quality improvement in IO for liver tumours - M. Calandri
ERT 279 – Personalised management of HCC patients: Europe meets China - 17:30–18:30 Room 113
279.3 / The role of ablation in guidelines and clinical practice
SP 276 – Advanced imaging guidance in IO - 17:30-18:30 Room 119
276.1 / Evaluation of ablation zone stability by applying CT-guided high-energy protocols in microwave ablation (MWA) post preablation transarterial chemoembolization (TACE) in malignant liver lesions: treatment response - T. Vogl
276.2 / Ablation of small liver metastases presenting as foci of diffusion restriction on mri–results from the prospective minimally invasive thermal ablation (MISTRAL) study - N. Wijnen
276.3 / Dual-layer spectral CT for in vivo thermometry during ablation - N. Varble
276.4 / Interim results from prospective multicenter neuwave observational liver ablation (NOLA) registry: hepatocellular carcinoma tumors -- Z. Haskal
276.5 / Is a >3cm tumor diameter still a valid contraindication for thermal ablation? Impact of tumor size on outcomes of hepatic arteriography and C-arm CT-guided ablation (HepACAGA) - N. Wijnen
276.6 / Effects of windowing and MIP reconstruction on deep learning performance for liver tumor segmentation - M. Seker
276.7 / Spectral cone-beam CT for in vivo liver imaging and ablation confirmation - N. Varble
Monday September 15th
CS 313 – Controversies in IO - 8:30-9:30 Room 117
313.2 / Pulmonary metastatic disease: pro ablation - L. Tselikas
313.4 / RCC T1a: pro ablation - D. Filippiadis
313.6 / Desmoids: start with percutaneous cryoablation - F. Cornelis
ERT 363 – CRC liver thermal ablation trials: is this really a paradigm shift? - 16:15-17:15 Room 117
363.1 / CIEMAR - F. Orsi
363.2 / COLLISION trial - M. Meijerink
363.3 / COVER-ALL - B. Odisio
363.4 / ACCLAIM trial - C. Sofocleous
Tuesday Sept 16th
FS 413 – Hot topics in lung ablation - 8:30–9:30 Room 117
413.1 / NSCLC: revisiting the guidelines R. Suh
413.2 / Chemo vacation and thermal ablation - S. Pernot
413.3 / Lung metastatic disease: how far can we go with ablation? - M. Calandri
413.4 / Update on lung ablation studies - M. Callstrom
ERT 425 – Interventional radiology and diagnostic radiology: is it time for a velvet divorce? - 10:00–11:00 Room 115
425.2 / How IR became an independent specialty in the USA, and how dual certification works - J. Kaufman
425.3 / You can talk the talk, but can you walk the walk? - B. Arslan
425.4 / Interventional and diagnostic radiology – is the link unbreakable? - A. Adam
CBD 423 – Lung ablation: real life hard-core complex cases - 10:00–11:00 Room 117
423.2 / Central tumor - F. Deschamps
423.3 / Thoracic wall - X. Buy
423.4 / Tumour lying immediatelly adjacent to aorta or pulmonary vessels - G. Carrafiello
FS 465 – Maximise the value of IR time -16:15–17:15 Room 114
465.1 / How I do it in my hospital - N. Gupta
465.2 / Lessons from the CIRSE clinical practice task force -A. Mahnken
465.3 / Lessons from overseas - D. Prologo
465.4 / How to build a business case - S. Anthony
ERT 463 – The rise of the machines - 16:15-17:15 Room 117
463.2 / Verification of safety margins - M. Burgmans
463.3 / Robotic systems for percutaneous applications: today and tomorrow - D. Madoff
463.4 / Artificial intelligence and augmented reality - F. Gómez Muñoz
ETF 472 – Developing IR - 17:30-18:30 News on stage
472.1 / Europe - K. Karlović
472.2 / Africa - F. Laage Gaupp
472.3 / South America - D. Barbosa
472.4 / Asia - T. Nguyen
Wednesday September 17th
FS 511 – Renal cell carcinoma - 8:30–9:30 Room 112
511.1 / Combining ablation and TAE - C. Georgiades
511.2 / T1b/T2: should we offer ablation? - A. Gunn
511.3 / Update on prospective RCC ablation studies - T. Azrumelashvili
511.4 / The role of IR in metastatic disease - M. Krokidis